EU approves Elixir Medical's bioresorbable heart stent

05/16/2013 | (Boston)

Elixir Medical has earned the CE mark to market its DESolve Novolimus-eluting coronary stent in Europe. The bioresorbable stent, which is used to treat patients with coronary artery disease, degrades in the body in about a year, restoring the treated vessel to its normal de novo state. The company aims for a limited global release of the device later in the year.

View Full Article in: (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA